Device Trial Radar · NCT02423005
Neurotech Vital Compact Versus Itouch Sure Pelvic Floor Exerciser US
Last checked: Nov 19, 2026Latest source record: Feb 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
180
Actual
Start
Apr 2015
Primary completion
Apr 2017
Study completion Apr 2017
Sponsor
- Lead sponsor
- Atlantic TherapeuticsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Bio-Medical Research, Ltd.
- First posted
- Apr 22, 2015
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- Female only, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A prospective, randomised, controlled, single-blind, multi-site clinical study employing Neuromuscular Electrical Stimulation (NMES) to stimulate the pelvic floor muscles of women suffering from stress urinary incontinence. Approximately one-hundred and eighty (180) female patients diagnosed with stress urinary incontinence will be enrolled in this study. All patients who are considered eligible to participate in the clinical study and give consent will be randomised to complete either a 12-week treatment programme with the Neurotech Vital Compact device or a 12-week treatment programme with the itouch Sure Pelvic Floor Exerciser. The 12-week treatment programme will be completed by the subjects at home with treatment with the device in accordance with the device Instructions for Use.
Conditions
- Stress Urinary Incontinence
Interventions
Neurotech Vital CompactDevice
Neuromuscular electrical stimulation of the pelvic floor via an arrangement of external electrodes held in place by a garment.
itouch Sure Pelvic Floor ExerciserDevice
Vaginal probe with electrodes designed to deliver electrical stimulation to the pelvic floor muscles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects who have achieved >50% improvement on the provocative pad weight test.Time frame: 12 weeks
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Maricopa Integrated Health Systems
Phoenix, Arizona
University of California Irvine Medical Center
Orange, California
Hartford Hospital
Hartford, Connecticut
9 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.